Every 13F-reported equity position this quarter with its quarter-over-quarter change; each row traces to the filer's 13F-HR on EDGAR.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR
Every 13F-reported equity position this quarter with its quarter-over-quarter change; each row traces to the filer's 13F-HR on EDGAR.
Royalty Pharma Sub-Manager, LLC (CIK 2081668) reported $241.9M across 4 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: CYTK ($83.5M, 34.52%), ZBIO ($60.6M, 25.05%), KLRA ($54.1M, 22.36%), BHVN ($43.7M, 18.06%), BCRX ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | CYTK | CYTOKINETICS, INC | $83.5M | 34.52% | 980,392 | Hold |
| 2 | ZBIO | ZENAS BIOPHARMA, INC. | $60.6M | 25.05% | 2.4M | Hold |
| 3 | KLRA | KAILERA THERAPEUTICS | $54.1M | 22.36% | 2.5M | New |
| 4 | BHVN | BIOHAVEN LTD | $43.7M | 18.06% | 2.9M | Hold |
| 5 | BCRX | BIOCRYST PHARMACEUTICALS INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30